A Phase 3 interventional study of Lifitegrast and Placebo in Dry Eye Disease, sponsored by Shire. Completed at 41 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-06-11.
Sponsored by Shire (part of Takeda) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 22 studies testing lifitegrast in Dry Eye Syndromes — 2 open to participants now, 2 under way, none of them phase 3. lifitegrast · Dry Eye Syndromes.
Among the 22 studies testing lifitegrast in Dry Eye Syndromes, this one is the 2nd largest by enrollment, is the only one that started in 2014, is one of 5 in phase 3, and was the 5th registered.
1,369 studies on the registry are indexed under Dry Eye Syndromes; 208 are open to participants now.
Browse Dry Eye Syndromes studies →2 of the 22 studies testing lifitegrast in Dry Eye Syndromes are open now, in 1 country. Recruiting first, the newest first:
Toyos Clinic · Sites in United States
Ages 18+
Pittsburgh Research Institute · Sites in United States
Ages 18+ · Healthy volunteers
By country, each count listing its studies:
lifitegrast: first FDA approval 2016 (XIIDRA). What it is approved for, and how studies give it, is on its page →
Of the 116 Dry Eye Syndromes studies recruiting now, 73 (63%) set no upper age limit and 24 (21%) stop at 75 or younger; 7 take children under 18; 29 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
22 studies; the count open now beside each. This study's row is marked.
First in 2009; this study’s year is marked. 1 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 711 is above the median of 60 across 1,129 interventional studies indexed under Dry Eye Syndromes.
Median enrollment 38 across the 22 interventional studies. Of the 14 that completed or were terminated, 7 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 22 have an industry lead sponsor. The 10 most frequent:
This study is registered under Shire, one of the names counted as Takeda. Under that name alone:
Shire is the lead sponsor of 351 studies on the registry; 2 are open to participants now.
Of its 48 completed or terminated interventional studies of FDA-regulated products, 48 (100%) have results posted.
Takeda has 5 studies filed under Dry Eye Syndromes — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 22 studies testing lifitegrast in Dry Eye Syndromes, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Evaluate the efficacy and safety of Lifitegrast in subjects with dry eye disease and a recent history of artificial tear use.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Lifitegrast Ophthalmic Solution 5%, BID for 84 days
Drug: Lifitegrast
Placebo to match active treatment, BID for 84 days
Drug: Placebo
Lifitegrast Ophthalmic Solution 5%, BID for 84 days
Placebo to match active treatment, BID for 84 days
Change From Baseline in Patient-Reported Eye Dryness Score to Day 84
Eye dryness score was scored on a Visual Analogue Scale (VAS) ranges from 0-100 (0=no discomfort; 100=maximal discomfort).
Time frame: Baseline to Day 84
Change From Baseline in Patient-Reported Eye Dryness Score to Day 14 and Day 42
Eye dryness score was scored on a Visual Analogue Scale (VAS) ranges from 0-100 (0=no discomfort; 100=maximal discomfort).
Time frame: Baseline to Day 14 and Day 42
| Milestone | Placebo | Lifitegrast |
|---|---|---|
| Started | 356 | 355 |
| Safety population | 354 | 357 |
| Completed | 318 | 319 |
| Not completed | 38 | 36 |
Eye dryness score was scored on a Visual Analogue Scale (VAS) ranges from 0-100 (0=no discomfort; 100=maximal discomfort).
| units on a scale | Placebo | Lifitegrast |
|---|---|---|
| Baseline (n=356, 355) | 69.0 ± 17.08 | 68.3 ± 16.88 |
| Change from Baseline to Day 84 (n=353, 353) | -30.7 ± 28.01 | -37.9 ± 28.85 |
Eye dryness score was scored on a Visual Analogue Scale (VAS) ranges from 0-100 (0=no discomfort; 100=maximal discomfort).
| units on a scale | Placebo | Lifitegrast |
|---|---|---|
| Baseline (n=356, 355) | 69.0 ± 17.08 | 68.3 ± 16.88 |
| Change from Baseline to Day 14 (n=353, 352) | -15.0 ± 22.40 | -22.9 ± 25.44 |
| Change from Baseline to Day 42 (n=353, 353) | -23.9 ± 25.99 | -33.2 ± 27.42 |
Collected over From start of the study drug administration upto Day 91 or Early termination (ET). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | — | 4/354 (1.1%) | 30/354 (8.5%) |
| Lifitegrast | — | 4/357 (1.1%) | 107/357 (30%) |
| Event | Placebo | Lifitegrast |
|---|---|---|
| Periprosthetic fractureInjury, poisoning and procedural complications | 1/354 | 0/357 |
| Lower limb fractureMusculoskeletal and connective tissue disorders | 1/354 | 0/357 |
| Basal cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/354 | 0/357 |
| Accelerated hypertensionVascular disorders | 1/354 | 0/357 |
| PneumoniaInfections and infestations | 0/354 | 1/357 |
| Cerebrovascular accidentNervous system disorders | 0/354 | 1/357 |
| Transient ischaemic attackNervous system disorders | 0/354 | 1/357 |
| Lung neoplasm malignantRespiratory, thoracic and mediastinal disorders | 0/354 | 1/357 |
| Event | Placebo | Lifitegrast |
|---|---|---|
| Instillation site irritationGeneral disorders | 11/354 | 65/357 |
| DysgeusiaNervous system disorders | 1/354 | 46/357 |
| Instillation site reactionGeneral disorders | 19/354 | 45/357 |
Randomized population included all participants screened for whom a randomization number was assigned.
| Age, Continuous(years) | Placebo | Lifitegrast | Total |
|---|---|---|---|
| Mean | 58.6 ± 14.84 | 58.8 ± 14.10 | 58.7 ± 14.47 |
| Sex: Female, Male(Participants) | Placebo | Lifitegrast | Total |
|---|---|---|---|
| Female | 269 | 268 | 537 |
| Male | 87 | 87 | 174 |
Ran from Nov 2014 to primary completion in Oct 2015, 10 months.
Results were first posted in Mar 2017, 1 year 5 months after primary completion.
Of 81 industry-sponsored phase 3 interventional studies under Dry Eye Syndromes, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 15. This study's 10 months is above that.
Counting every sponsor, half of 96 studies reached it within 10 months; a quarter within 7 and three quarters within 15.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Lifitegrast